Having trouble accessing articles? Reset your cache.

Zentalis debuts with trio of clinical oncology programs, $85M series C

Zentalis has raised total of $147M to pursue targets in 'fundamental' cancer pathways

Zentalis emerged from stealth Monday with an untranched and oversubscribed $85 million series C and three internally discovered clinical cancer candidates, with plans to begin pivotal testing by 2021.

The C round syndicate includes Matrix Capital, Viking Global Investors, Redmile Group, Farallon Capital, Perceptive Advisors, Surveyor Capital, Eventide Asset Management, Alexandria, Pharmaron Beijing Co. Ltd. (SZSE:300759), Highlight Capital, Mayo Clinic and high net worth individuals. Most of the firms had previously

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE